Drug
BI 1815368
BI 1815368: highest development phase Phase 2, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BI 1815368 NCT06962839 | Phase 2 | Macular Edema |
Latest
No recent events.
Follow BI 1815368 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.